Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) EBITDA (2016 - 2025)

Historic EBITDA for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to -$2.0 million.

  • Ernexa Therapeutics' EBITDA rose 1177.51% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.9 million, marking a year-over-year increase of 4706.54%. This contributed to the annual value of -$15.7 million for FY2024, which is 2583.87% up from last year.
  • Ernexa Therapeutics' EBITDA amounted to -$2.0 million in Q3 2025, which was up 1177.51% from -$2.5 million recorded in Q2 2025.
  • Over the past 5 years, Ernexa Therapeutics' EBITDA peaked at -$2.0 million during Q3 2025, and registered a low of -$86.3 million during Q3 2021.
  • Over the past 5 years, Ernexa Therapeutics' median EBITDA value was -$5.3 million (recorded in 2023), while the average stood at -$10.1 million.
  • As far as peak fluctuations go, Ernexa Therapeutics' EBITDA crashed by 572945.95% in 2021, and later surged by 9037.51% in 2022.
  • Quarter analysis of 5 years shows Ernexa Therapeutics' EBITDA stood at -$86.3 million in 2021, then soared by 94.51% to -$4.7 million in 2022, then decreased by 21.7% to -$5.8 million in 2023, then surged by 53.22% to -$2.7 million in 2024, then increased by 26.1% to -$2.0 million in 2025.
  • Its EBITDA stands at -$2.0 million for Q3 2025, versus -$2.5 million for Q2 2025 and -$2.7 million for Q1 2025.